What do systematic reviews say?

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in death compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.99 [0.69, 1.4]
  23 studies · 5427 participants
  Moderate

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… probably leads to higher acute rejection compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.43 [1.15, 1.78]
  30 studies · 5903 participants
  Moderate

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in graft loss compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.94 [0.75, 1.19]
  25 studies · 5446 participants
  Low

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.86 [0.64, 1.15]
  7 studies · 2207 participants
  Low

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… probably leads to lower adverse events: CMV Infection compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.6 [0.44, 0.82]
  13 studies · 2503 participants
  Moderate

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.69 [0.47, 1]
  14 studies · 3699 participants
  Low

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: lymphocele compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.45 [0.95, 2.21]
  8 studies · 1926 participants
  Low

Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late withdrawal with… probably leads to higher acute rejection: late withdrawal compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.9 [1.44, 2.51]
  17 studies · 3636 participants
  Moderate

Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  14 studies · 2679 participants
  Low

Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late withdrawal with… showed no clear difference in graft loss: late withdrawal compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.92 [0.65, 1.3]
  17 studies · 4026 participants
  Moderate

Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late withdrawal with… showed no clear difference in acute rejection: avoidance compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.27 [0.98, 1.65]
  11 studies · 1844 participants
  Moderate

Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 1748 participants
  Low

Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late withdrawal with… showed no clear difference in graft loss: avoidance compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.03 [0.72, 1.48]
  8 studies · 1420 participants
  Moderate